**PRODUCT INFORMATION**

**Content:** 100 µg anti-hVEGF-hIgG1, purified antibody, provided azide-free and lyophilized

**Specificity:** Vascular endothelial growth factor (VEGF)

**Isotype:** Human IgG1

**Light chain type:** kappa

**Source:** CHO cells

**Formulation:** 0.2 mM filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents

**Antibody resuspension**

Add 1 ml of sterile water to obtain a concentration of 0.1 mg/ml

**Storage**

- Product is shipped at room temperature. Store lyophilized antibody at -20 °C. Lyophilized product is stable for at least 1 year.
- Reconstituted antibody is stable for 1 month when stored at 4 °C and for 1 year when aliquoted and stored at -20 °C. Avoid repeated freeze-thaw cycles.

**Quality control**

- Binding of anti-hVEGF-hIgG1 to human VEGF has been tested using indirect ELISA.
- The complete sequence of this antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

**DESCRIPTION**

Anti-hVEGF-hIgG1 features the constant region of the human IgG1 isotype and the variable region of bevacizumab. Bevacizumab is a humanized IgG1 monoclonal antibody that targets VEGF, a signaling protein that promotes the growth of new blood vessels. In many cancers VEGF is overexpressed, thereby promoting tumor growth and angiogenesis. The overexpression of VEGF can also lead to vascular disease, particularly in the retina. Bevacizumab neutralizes VEGF and blocks its signal transduction through the VEGF receptors1. Consequently, bevacizumab blocks downstream pathways which regulate cell growth and angiogenesis. Bevacizumab displays no antibody-dependent cell-mediated cytotoxicity (ADCC). Bevacizumab has been approved by the FDA for the treatment of certain types of brain, colorectal, lung, kidney, and ovarian cancers.

Anti-hVEGF-hIgG1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

**ANTIBODY ISOTOYPE COLLECTION**

For your research, InvivoGen provides an anti-hVEGF isotype family. This isotype family consists of monoclonal antibodies comprising the variable region of bevacizumab, and the constant region of three different human isotypes; IgG1, IgG4, and IgA2. The isotypes differ in their functional locatrons and effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as presented in the table below.

<table>
<thead>
<tr>
<th>Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human IgG1</td>
<td>Most abundant IgG present in serum</td>
</tr>
<tr>
<td></td>
<td>High CDC, high ADCC</td>
</tr>
<tr>
<td>Human IgG4</td>
<td>Least common IgG present in serum</td>
</tr>
<tr>
<td></td>
<td>No CDC, low ADCC</td>
</tr>
<tr>
<td>Human IgA2</td>
<td>Major class in secretions, oligomeric forms, highly resistant to enzymatic degradation. No CDC, low ADCC</td>
</tr>
</tbody>
</table>

**RELATED PRODUCTS**

<table>
<thead>
<tr>
<th>Product</th>
<th>Catalog Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-hVEGF-hIgA2</td>
<td>hvegf-mab7</td>
</tr>
<tr>
<td>Anti-hVEGF-hIgG4 (S228P)</td>
<td>hvegf-mab14</td>
</tr>
</tbody>
</table>

Other antibody isotype families are available, such as Anti-hCD20, Anti-hPD1 and Anti-fGal (control).

For more information visit www.invivogen.com/antibody-isotypes.

---